The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that ...

GLP-1 RA drugs help treat diabetes by weight loss, improving blood glucose levels and increasing insulin sensitivity, low ...

Trump could keep Biden’s commitment to have Medicare pay for weight loss drugs such as Ozempic and Wegovy. But would ...

2025's top drug targets Obesity is positioned to be biopharma's hottest market in 2025, Roop predicted. Related stories 2024's biggest pharma acquisition was in obesity. Novo Nordisk's controlling ...

The drug Zepbound might not have the same name recognition as Ozempic, but it's another in the class to treat obesity and ...

Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...

Two of President-elect Trump’s top health nominees are on a collision course as the incoming administration faces a crucial ...

A 2024 study in the American Journal of Managed Care found that patients’ health care costs declined by $7,502 after they began treatment with the anti-obesity drug semaglutide. Importantly ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20 percent of their body weight, on average, a result that caused the Danish ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock ...